James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.
“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”
Wall Street Journal, November 23
Michael Greenberg: Master Synthesizer of Risk, Public Health, and Public Policy by Joanna Burger & Karen W. Lowrie Michael Greenberg is an extraordinary researcher, teacher, and pioneer who has combined his broad knowledge and expertise in environmental...
A new article in the Journal for STEM Education Research challenges the longstanding “leaky pipeline” narrative that has shaped U.S. education and workforce policy for decades. The article, “Reconceptualizing College STEM Pathways: Is ‘Leaving STEM’ the Problem?”, was...
New Jersey’s New E-Bike Laws: Safety, Impact, and What Comes Next Leigh Ann Von Hagen & Gabrielle Cain In recent years, e-bikes have become an increasingly popular form of micromobility, which are small, lightweight transportation devices designed for short trips...
Researchers at the Heldrich Center for Workforce Development, with funding from the New Jersey State Policy Lab, are currently engaged in a project to examine how New Jersey’s public Artificial Intelligence (AI) initiatives can better align with the evolving needs of...
Planning, Policy, Politics, and the Path to Office with Assemblywoman Katie Brennan This week on EJB talks, Dean Stuart Shapiro talks to Bloustein alumnus Katie Brennan MCRP '12, now an Assemblywoman in New Jersey's 32nd District. Katie reflects on how her early...